CuraGen advances melanoma drug into Phase II trial

CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against glycoprotein NMB (GPNMB) attached to a potent, synthetic drug monomethyl auristatin E (MMAE), using Seattle Genetics’s proprietary technology.

Ronit Simantov, vice president of medical development and chief medical officer of CuraGen, said: “We are pleased with the progress achieved in the CR011-vcMMAE clinical program. Advancing this program into Phase II is an important development milestone as we look to establish the role of CR011-vcMMAE in the treatment of patients with advanced melanoma.”